Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01431
|
|||||
Drug Name |
Famciclovir
|
|||||
Synonyms |
FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Viral infections [ICD11: 1D90-1D9Z] | Approved | [1] | |||
Therapeutic Class |
Antiviral Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C14H19N5O4
|
|||||
Canonical SMILES |
CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
|
|||||
InChI |
InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)
|
|||||
InChIKey |
GGXKWVWZWMLJEH-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 104227-87-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 321.33 | Topological Polar Surface Area | 122 | ||
Heavy Atom Count | 23 | Rotatable Bond Count | 9 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
XLogP |
0
|
|||||
PubChem CID | ||||||
PubChem SID |
626303
, 5276651
, 7847383
, 7979216
, 8152111
, 11363360
, 11365922
, 11368484
, 11372808
, 11374301
, 11376646
, 11484938
, 11488917
, 11491490
, 11492426
, 11494280
, 11528705
, 12013946
, 14899331
, 26612822
, 26680213
, 26719883
, 26748972
, 26748973
, 26758694
, 29222459
, 46386745
, 46507561
, 47291220
, 47515410
, 48415997
, 49681753
, 50107498
, 52712677
, 53800778
, 56313627
, 57321725
, 68530529
, 81092805
, 85173809
, 85787983
, 92124793
, 92308042
, 92308372
, 92309126
, 92710468
, 103158204
, 103231964
, 104253634
, 104303176
|
|||||
ChEBI ID |
CHEBI:4974
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Famciclovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.